康希诺生物股份公司第三季度营收3.10亿元,非GAAP净利润304.48万元

公告速递
Oct 27

本季度信息

2025年第三季度,康希诺生物股份公司营业收入达到3.10亿元,同比增长17.67%。同期非GAAP净利润为304.48万元。综合毛利率为80.67%,较去年同期提升6.47个百分点。公司经营活动现金流由上年同期净流出转为本期净流入,第三季度实现约2221.82万元净流入。研发投入约占营收的29.19%,较去年同期下降11.74个百分点。

业务分项

公司主要收入仍由四价流脑结合疫苗“曼海欣®”拉动,该产品凭借创新优势和市场认可度持续上升,带动整体营收增长。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10